Treace Medical Concepts Third Quarter 2026 Earnings Conference Call - TREACE MEDICAL CONCEPTS INC

Financial Performance:

• Q3 2026 revenue was $48.3 million, a 4% year-over-year (YoY) decrease, primarily driven by revenue mix shifts toward lower-priced minimally invasive products and a decline in bunion procedure kit volume.
• Excluding sales to stocking distributors, bunion kit sales volume increased, and revenue grew mid-single digits YoY.
• Gross margin improved to 79.5% in Q3 2026 from 79.1% in Q3 2025.
• Total operating expenses decreased 10% YoY to $49.9 million (down $5.5 million).
• Third-quarter net loss narrowed 23% to $12.6 million ($0.19/share) from $16.3 million ($0.26/share) in the prior year.
• Adjusted EBITDA turned positive at $0.3 million for Q3 2026, compared to a $2.6 million loss in Q3 2025.
• Year-to-date cash usage reduced by 53% ($9.7 million) compared to the same period in 2025.
• Cash equivalents and marketable securities stood at $39.8 million as of September 30, 2026.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance narrowed to $206 million–$210 million (previously $204 million–$212 million), representing a projected 3% to 1% decline from 2025.
• Full-year 2026 adjusted EBITDA loss guidance updated to $1 million–$2 million (previously $3.9 million loss).
• Management expects revenue growth to resume in Q4 2026, driven by seasonally higher procedure volumes, lapping lower ASPs from 2025 product launches, and the impact of 2026 product introductions.
• Full-year 2026 cash usage is expected to decrease by approximately 50% compared to 2025.
• 2027 guidance will be provided during the Q4 earnings call after gaining more visibility on Q4 performance and new product traction.

Business Segments and Product Lines:

• The company launched three new bunion systems in Q3 2025 (Nanoplasty, Percuplasty, Speed MTP) to address 75% of the bunion market beyond Laplacia, reaching 45% adoption among existing Laplacia surgeons in Q3.
• Q3 2026 saw the full commercial launch of the SuperBite compression screw system and the HyperPlate XM dynamic compression locking implants for mid/hindfoot fusions.
• VitaFuse bioactive glass graft and Cartoblaster power rasps were introduced in Q3, with full commercialization expected in Q4 2026; collectively, these four new products expand U.S. TAM by an estimated $400 million.
• The Taylor Plasty system for bunionettes was successfully trialed in Q3, with full commercialization planned for Q1 2027.
• Laplacia Lightning (faster procedure platform) and IntelliGuide PSI (patient-specific planning) are in final preparation for Q1 2027 launch.
• Management estimates the expanded portfolio now serves 80%+ of an average surgeon's reconstructive foot and ankle surgery volumes, up from 30% previously.

Market and Competitive Landscape:

• The company reported double-digit case volume growth in Q3 2026, contrasting with slowing procedure volumes noted by other industry peers.
• Laplacia remains the market leader in the Lapidus fusion segment, which accounts for approximately 30% of U.S. bunion procedures.
• The new bunion systems target the high-volume osteotomy and MTP fusion markets to capture broader wallet share.
• Market share gains are attributed to the adoption of a comprehensive portfolio rather than a single product.

Risks and Challenges:

• ASP mix dynamics: The introduction of lower-priced minimally invasive products has temporarily reduced revenue per case, though high-reimbursement complex cases in the mid/hindfoot provide a counterbalance.
• Stocking distributor orders: Significant revenue impact from stocking distributor sales observed in Q3 2025 is expected to decrease significantly in Q4, aiding the return to growth.
• Market-wide procedure volume trends: While the company sees growth, broader market trends remain a variable to monitor.

Management Commentary and Tone:

• Management tone is confident and optimistic, emphasizing a "return to growth" in Q4 and long-term strategic execution.
• CEO John Treese highlighted the successful validation of the strategy to expand from a single-product focus to a comprehensive foot and ankle technology partner.
• CFO Mark Hare expressed satisfaction with the improved operating leverage, noting that despite revenue decline, EBITDA improved significantly and cash usage was halved.
• Management confirmed a commitment to maintaining focus on the core Laplacia anchor while seamlessly integrating new adjacent procedures.

Analyst Questions and Answers:

• ASP vs. Volume Dynamics: John Treese noted that while ASPs may decrease slightly due to MIS product adoption, the broader portfolio allows entry into high-ASP complex cases, balancing the mix long-term.
• Adoption Rates: Ben Hainer asked about adoption tracking; Treese indicated 45% of Laplacia surgeons adopted new systems in Q3 (up from 40% in Q2) and expects continued deepening of adoption to 100% usage of the full portfolio.
• International Expansion: Management acknowledged international potential but stated no specific timeline until the portfolio is more mature and material developments occur.
• Marketing Trademarks: Ben Hainer joked about "Cardi B" endorsing the "Cartoblaster"; management humorously confirmed they protect trademarks but declined to comment on specific celebrity endorsements.
• Q4 Revenue Guidance: Rick Wise asked why the upper guidance was lowered despite a Q3 sales beat; Hare explained the upper range cut reflects conservative visibility while the Q4 outlook remains strong due to volume growth.
• Reorder/Repeat Metrics: Treese reported high stickiness and repeat adoption rates among surgeons adopting new systems, with growing usage of 2+ and 3+ product categories per surgeon.
• Sales Headcount and OpEx: Kunal Neweter asked about rep productivity; John Treese confirmed plans for modest, incremental sales channel expansion, while Mark Hare reiterated that most sales costs are variable (commissions) and no dramatic OPEX increases are anticipated.

Other Key Points:

• Five-year clinical data for Laplacia (Align3D study) demonstrated low recurrence rates and significant pain reduction, reinforcing the product as the "gold standard."
• The company views the expanded portfolio as a "one-stop-shop" strategy to reduce surgeon reliance on competitive systems for bone grafts, fixation, and rasps.
• Management highlighted the synergy of having the sales force serve both high-volume bunion cases and lower-volume but high-value mid/hindfoot procedures in the same visits.